ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 4 for:    KN035

A Study of PD-L1 Antibody KN035 in Japanese Subjects With Locally Advanced or Metastatic Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03248843
Recruitment Status : Recruiting
First Posted : August 14, 2017
Last Update Posted : January 18, 2018
Sponsor:
Information provided by (Responsible Party):
3D Medicines (Sichuan) Co., Ltd.

Brief Summary:
This is an open label, dose escalation study to evaluate the safety and tolerability of KN035 in Japanese patients with advanced and metastatic solid tumor. The dose escalation will follow the widely used 3+3 design.

Condition or disease Intervention/treatment Phase
Advanced or Metastatic Solid Tumors Drug: KN035 Phase 1

Detailed Description:

This is an open label, dose escalation study to evaluate the safety and tolerability of KN035 in Japanese patients with advanced and metastatic solid tumor.

The dose escalation will follow the widely used 3+3 design. Cohorts of 3-6 subjects will be enrolled sequentially at escalating doses of 1.0, 2.5, 5.0 and 10 mg/kg weekly. Dose escalation will continue until identification of MTD up to a maximum dose of 10 mg/kg. MTD is defined as the highest dose studied at which no more than 1 of 6 subjects has experienced a dose-limiting toxicity (DLT) in Cycle 1. The enrolled patients are managed under hospitalization for DLT observation period (C1 28 days). If no DLTs occur in a cohort of 3 subjects, a new cohort of 3 subjects will be treated at the next higher dose level. If 1 of 3 subjects in a cohort experiences a DLT, that cohort will be expanded to 6 subjects. If only 1 of the 6 subjects has a DLT, then the next cohort of 3 subjects will be treated at the next higher dose level. If 2 or more DLTs occur within a cohort, then that dose level will be above the MTD, and the previous lower (tolerated) dose level will be considered the MTD if ≤ 1 in 6 subjects has a DLT.

A subject who withdraws from the study during Cycle 1 for reasons other than a DLT will be replaced.

Subjects will be monitored for safety and efficacy throughout the study. After radiological tumor assessment at Screening, the first radiological assessment of tumor response status will be performed at Week 12 (± 1 week), unless there is clinical indication warranting earlier radiologic imaging. The same imaging technique used at baseline has to be used throughout the study.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 18 participants
Intervention Model: Single Group Assignment
Intervention Model Description: Cohorts of 3-6 subjects will be enrolled sequentially at escalating doses of 1.0, 2.5, 5.0 and 10 mg/kg of KN035 weekly.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I, Open Label, Dose Escalation Study of The Safety and Pharmacokinetics of Anti-PD-L1 Monoclonal Antibody KN035 Administered in Subcutaneous Injection as A Single Agent to Japanese Subjects With Locally Advanced or Metastatic Solid Tumors
Actual Study Start Date : September 15, 2017
Estimated Primary Completion Date : April 2018
Estimated Study Completion Date : December 2018

Arm Intervention/treatment
Experimental: KN035
Cohorts of 3-6 subjects will be enrolled sequentially at escalating doses of 1.0, 2.5, 5.0 and 10 mg/kg weekly. Dose escalation will continue until identification of MTD up to a maximum dose of 10 mg/kg.
Drug: KN035
Four cohorts dosed at 1.0 mg/kg, 2.5 mg/kg, 5.0 mg/kg, and 10 mg/kg weekly. All cohorts are administered by subcutaneous injection (SC).




Primary Outcome Measures :
  1. Incidence of dose limiting toxicities [ Time Frame: From screening to up to cycle 1 (28 days) ]
  2. KN035 safety and tolerability assessed by monitoring AEs per the NCI-CTC-AE Version 4.03, physical examination, electrocardiograms, laboratory measurements and severity of adverse events [ Time Frame: From screening to up to 1 months after the last dose of study drug (up to approximately 2 years ]
    The safety of KN035 will be assessed throughout the study by monitoring adverse events (AEs) per the NCI-CTC-AE Version 4.03, physical examination, electrocardiograms, laboratory measurements and severity of adverse events.


Secondary Outcome Measures :
  1. Peak Plasma Concentration (Cmax) of KN035 in Japanese patients [ Time Frame: From Pre-dose of the first dose to up to 48 weeks ]
  2. Peak Time (Tmax) of KN035 in Japanese patients [ Time Frame: From Pre-dose of the first dose to up to 48 weeks ]
  3. Area under the plasma concentration versus time curve (AUC) of KN035 in Japanese patients [ Time Frame: From Pre-dose of the first dose to up to 48 weeks ]
  4. t1/2 of KN035 in Japanese patients [ Time Frame: From Pre-dose of the first dose to up to 48 weeks ]
  5. Trough concentration of KN035 in Japanese patients [ Time Frame: From Pre-dose of the first dose to up to 48 weeks ]
  6. Plasma clearance (CL) of KN035 in Japanese patients [ Time Frame: From Pre-dose of the first dose to up to 48 weeks ]
  7. Apparent volume of distribution of KN035 in Japanese patients [ Time Frame: From Pre-dose of the first dose to up to 48 weeks ]
  8. Accumulation rate of KN035 in Japanese patients [ Time Frame: From Pre-dose of the first dose to up to 48 weeks ]
  9. Anti-Drug Antibody of KN035 in Japanese patients [ Time Frame: From Pre-dose of the first dose to up to 48 weeks ]
  10. Changes of lymphocyte Subtyping [ Time Frame: From Pre-dose of the first dose to up to 48 weeks ]
  11. Changes of cytokine [ Time Frame: From Pre-dose of the first dose to up to 6 months ]
  12. Objective Response Rate (ORR) [ Time Frame: Up to 2 approximately years ]
  13. Disease Control Rate (DCR) [ Time Frame: Up to 2 approximately years ]
  14. Progression-Free survival (PFS) [ Time Frame: Up to 2 approximately years ]
  15. Duration of Response (DOR) [ Time Frame: Up to 2 approximately years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects must have a histological or cytological diagnosis of any type of carcinoma, progressive metastatic disease, or progressive locally advanced disease not amenable to local therapy. Subjects must have no standard anti-cancer therapy option, who failed established standard medical anti-cancer therapies for a given tumor type.
  • Subject is male or female and ≥ 18 years of age on the day of signing informed consent. However, in case a subject is younger than 20 years old, written informed consent will be obtained from both a subject and a legal representative.
  • Subject must have a performance status of 0 to 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale.
  • Subject must have adequate hematologic and organ function.
  • Subject has voluntarily agreed to participate by giving written informed consent.
  • Women able to get pregnant has a negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. The serum pregnancy test must be negative for the subject to be eligible.
  • Female subjects enrolled in the study must be willing to use either 2 adequate barrier methods or a barrier method plus a hormonal method of contraception to prevent pregnancy or to abstain from heterosexual activity throughout the study, starting with Informed Consent through 120 days after the last dose of study therapy. Women who have had a surgical hysterectomy and/or bilateral oophorectomy, or who are postmenopausal and have not had a menstrual cycle for 12 consecutive months without medical/medicinal reasons are not considered to be of childbearing potential. Approved contraceptive methods include for example; intra uterine device, diaphragm with spermicide*, cervical cap* with spermicide*, male condoms, or female condom *with spermicide* and hormonal method of contraception. Spermicides alone are not an acceptable method of contraception. *: not approved/certified in Japan.

Male subjects must agree to use an adequate method of contraception starting with Informed Consent through 120 days after the last dose of study therapy.

Exclusion Criteria:

  • Subject who not recovered from the effects of any prior chemotherapy, radioactive, or biological cancer therapy prior to the first dose of study therapy (for prior cancer therapy drugs, a washout of 5 half-lives or 28 days whichever is shorter is required), or who has not recovered to CTCAE Grade 1 or better from the adverse events due to cancer therapeutics administered more than 4 weeks earlier. Subject who has had erlotinib, gefitinib, afatinib, or crizotinib within 1 week prior to the first dose of study therapy, or who has not recovered to CTCAE Grade 1 or better from the adverse events due to any of these drugs administered more than 1 week earlier. Grade 2 alopecia is allowed to enter.
  • Subject is expected to require any other form of antineoplastic therapy while on study (including maintenance therapy with another agent for NSCLC).
  • Subject had prior treatment targeting PD-L1. Subjects with prior treatment targeting PD-1 are allowed to enroll if the subject has a washout time of at least 4 weeks. Examples of such anti-PD-L1 agents include (but are not limited to): BMS-936559 (MDX 1105); MPDL3280A (RG7446); and MEDI4736.
  • Subject has a medical condition that requires chronic systemic steroid therapy or requires any other form of immunosuppressive medication. However, subjects using physiologic replacement doses of hydrocortisone, or its equivalent, will be considered eligible for this study: up to 20 mg of hydrocortisone (or 5 mg of prednisone) in the morning and 10 mg of hydrocortisone (or 2.5 mg of prednisone) in the evening. Topical, intraocular, and intranasal steroids are allowed.
  • Subject has risk factors for bowel obstruction or bowel perforation (examples include but not limited to a history of acute diverticulitis, intra-abdominal abscess, or abdominal carcinomatosis).
  • Subject has a known history of a hematologic malignancy, malignant primary brain tumor or malignant sarcoma, or of another malignant primary solid tumor, unless the subject has undergone potentially curative therapy with no evidence of that disease for 5 years.
  • Subject has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are clinically stable for at least 4 weeks prior to study entry, have no evidence of new or enlarging brain metastases and are off steroids for at least 7 days from first dose of KN035.
  • Subject previously had a severe hypersensitivity reaction to treatment with another mAb.
  • Subject has a history of pneumonitis or interstitial lung disease irrespective of causes (For the purpose of screening of interstitial lung disease, chest X-ray, Sialylated carbohydrate antigen (KL-6) (hereafter, KL-6), percutaneous arterial blood oxygen saturation (hereafter, SpO2) and auscultation are conducted).
  • Subject has an active autoimmune disease or a documented history of autoimmune disease or syndrome that requires systemic steroids or immunosuppressive agents. Subjects with vitiligo or resolved childhood asthma/atopy would be exception to this rule. Subjects that require intermittent use of bronchodilators or local steroid injections would not be excluded from the study. Subjects with hypothyroidism that is stable on hormone replacement will not be excluded from the study.
  • Subject has an active infection requiring therapy.
  • Subject is positive for Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies), active hepatitis B (HBsAg reactive) or hepatitis C (HCV RNA (qualitative) is detected); subjects with negative hepatitis C antibody testing may not need RNA testing.
  • Subject has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating Investigator.
  • Subject has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
  • Subject has a marked baseline prolongation of QT/QTc (Fridericia's formula) interval (e.g., repeated demonstration of a QTc interval >450 milliseconds (ms) as a guidance considering the patient's background of physiological conditions), or a history of additional risk factors for torsade de pointes (TdP, e.g., heart failure, hypokalemia, family history of Long QT Syndrome), or is using concomitant medications that prolong the QT/QTc interval.
  • Subject is, at the time of signing informed consent, a regular user (including "recreational use") of any illicit drugs or had a recent history (within the last year) of substance abuse (including alcohol).
  • Subjects with symptomatic ascites or pleural effusion. A subject who is clinically stable following treatment for these conditions (including therapeutic thoraco- or paracentesis) is eligible.
  • Subject is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study. However, breastfeeding female subject who stopped breastfeeding can be included only if she agrees to stop breastfeeding during the treatment of the investigational drug and to restart breastfeeding 120 days after the last dose of the investigational drug.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03248843


Locations
Japan
St. Marianna University School of Medicine Hospital Recruiting
Kawasaki, Japan, 216-8511
Contact: Takako Nakajima, MD    044-977-8111    tnakajima@marianna-u.ac.jp   
Principal Investigator: Takako Nakajima, MD         
National Cancer Center Hospital Recruiting
Tokyo, Japan, 104-0045
Contact: Toshio Shimizu, MD    +81 3-354-2511 ext 7003    tosshimi@ncc.go.jp   
Principal Investigator: Toshio Shimizu, MD         
Sponsors and Collaborators
3D Medicines (Sichuan) Co., Ltd.

Responsible Party: 3D Medicines (Sichuan) Co., Ltd.
ClinicalTrials.gov Identifier: NCT03248843     History of Changes
Other Study ID Numbers: KN035-JP-001
First Posted: August 14, 2017    Key Record Dates
Last Update Posted: January 18, 2018
Last Verified: January 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by 3D Medicines (Sichuan) Co., Ltd.:
KN035
Solid tumors
Phase 1

Additional relevant MeSH terms:
Antibodies
Immunologic Factors
Physiological Effects of Drugs